Clinical Trials
4 trialsNCT06630221 2026-06-05
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Suspended
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed